about
Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected populationBoceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.Prognostic factors in left-sided endocarditis: results from the Andalusian multicenter cohortDifferences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patientsShort communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis CShould screening for Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-men who have sex with men be recommended?Monotherapy with darunavir/ritonavir is effective and safe in clinical practiceLow risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term.Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection.[Syphilis and human immunodeficiency virus infection: an endemic infection in men who have sex with men].[Intrafamilial, non-sexual, transmission of the human immunodeficiency virus]Serum ferritin in HIV-positive patients is related to immune deficiency and inflammatory activity.Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy.Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.[Enterococcal endocarditis: a multicenter study of 76 cases].[Multiple skin nodules, pancytopenia, and a solitary lung nodule in an HIV-infected patient].Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy.Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy.Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.HIV infection in the era of highly active antiretroviral therapy: the Malaga Study.A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients.Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients.Liver stiffness correlates with Child-Pugh-Turcotte and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis.Syphilis in HIV-infected patients: predictors for serological failure and serofast state.[Bacteremia and recurrent arthritis caused by Streptococcus pyogenes in a heroin addict with AIDS]Platelet activity in HIV-infected patients on abacavir-containing antiretroviral therapy.High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain BEfficacy of Low-Dose Boosted Saquinavir Once Daily Plus Nucleoside Reverse Transcriptase Inhibitors in Pregnant HIV-1-Infected Women With a Therapeutic Drug Monitoring Strategy[Retrospective epidemiological study on the durability of the treatment of HIV infection or AIDS in Spain]Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated with Highly Active Antiretroviral TherapyCandidemias: análisis multicéntrico en 16 hospitales andalucesInsulin resistance is associated with liver stiffness in HIV/HCV co-infected patientsLung cancer in HIV-infected patientsIn vitro susceptibilities of bloodstream isolates of Candida spp.: results from a multicenter active surveillance program in AndalusiaLiver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C
P50
Q28538921-D85A7A26-23EA-43AB-8133-34F4C742BA12Q33422417-B7DF30A6-5DC1-4FA4-AEF5-A3A6087AFF53Q33526060-8BD8D229-9DF2-4E83-AAC7-FAB587A2448BQ34473823-96A4D52D-627A-480D-8634-4DE3CD56D527Q36553967-7FF032A1-5E8A-4A49-8860-9B2A3F2435ACQ37842987-054F17A5-4A00-4956-A733-CD7FEB18831BQ39197751-6A34C8CD-DEE2-448F-B5C6-D6722CFDED67Q41578791-90BC1AEA-0A8B-4894-9470-81299EDA3455Q41620769-4E532A10-0576-4002-A4EA-0DB4F55484C9Q41638225-64CC0D9A-BA54-4FC6-8CC6-8839CC0575C4Q41993856-65042DF5-447A-4E51-8D1D-EEF13BE51D00Q42213463-D4E29EED-B1E6-4690-B2D7-BA45A057E54BQ42226571-F1672AEF-5404-4D2D-A82D-7181215973F0Q42246659-3A9369A6-7DB1-440F-ACA4-F4CD1395ADA4Q42251075-6EF946E3-5C46-4F6E-AE04-D668B1F466DCQ42977009-5D296BE4-AEB7-411B-9159-27E5D4D2DF8BQ42981205-8AD8116C-E776-4196-9523-EE5B02DADE92Q43037839-18B0E4E8-B65B-4CA2-9320-67AEA97C87A3Q43576953-E1611DDA-C6FE-4C5D-A0A7-BEB1CB25E728Q43993797-EE8ED008-3D21-4734-8E38-E5EA4D8174EEQ44087385-3031B1F7-D652-46F8-8E12-B12F77547AA8Q44190464-12EB862D-FE7F-4516-8BC2-CFF6A85F2B7CQ44461030-6061685C-C370-495B-B42F-21F4F9CBBD85Q44554477-31C7FA05-3D43-4016-9EAC-5D94F5D65EF5Q44754239-D3632FFB-BA4B-4D8E-B409-5BF6C3AE3F31Q45350906-4F84CA07-74A6-4F3D-8CAD-C08BEB2E7BCCQ45358296-AE170303-9886-4459-BE00-0E15B7667147Q45359060-4D0E6C14-C23D-4477-8EE8-36064DC11E0BQ50281566-5980F4A0-58E1-4FFB-BCD9-6CAACA62415DQ52272370-2E439D6C-8CB8-4759-806A-9954B8506A57Q55429361-DD5B81C3-7938-4767-9D23-188FCE0D42DEQ57106637-7549D997-6632-4414-9AEC-95FB6C0D8B9EQ58006165-0C69AA22-303C-4289-B0E7-1BC9C3364EC7Q58006195-33A2FE4D-D165-4623-85FE-D9DD8E68B862Q58204816-0086BD80-3F7F-42EC-9580-7F19AE2B290AQ59617446-C4EFFB40-09B0-4F16-B1AB-1C3FDF26C6C3Q59617479-63D9C26B-DAF4-4EB8-9DCB-22BEB7301FE5Q60515243-016D6158-21B8-4454-979F-62EF16494672Q61832615-87980BDF-E9E2-4E42-8FBA-F0C55CD5B880Q63242732-4C7E293B-C8A0-410C-8B25-753DDA06F092
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Manuel Marquez
@ast
Manuel Marquez
@en
Manuel Marquez
@es
Manuel Marquez
@nl
type
label
Manuel Marquez
@ast
Manuel Marquez
@en
Manuel Marquez
@es
Manuel Marquez
@nl
prefLabel
Manuel Marquez
@ast
Manuel Marquez
@en
Manuel Marquez
@es
Manuel Marquez
@nl
P106
P21
P31
P496
0000-0002-7901-6966